Fig. 4From: Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapiesResults of deterministic sensitivity analyses for FAc 0.2 μg/day implant vs. usual care in the pseudophakic populationBack to article page